CRESTBRIDGE
25.7.2022 16:48:05 CEST | Business Wire | Press release
Crestbridge, the agile alternative for private equity and real estate administration solutions, today announced the appointment of Anne Catherine Grave as Country Head of Luxembourg.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220725005497/en/
Based in Luxembourg, Anne Catherine will be responsible for leading the business in the region and building on its reputation as a leading service provider for fund managers.
Since establishing a presence in Luxembourg 11 years ago, Crestbridge has continued its commitment to quality, evolving its service proposition in line with the jurisdiction’s own exponential growth. This is testament to Crestbridge’s popularity amongst fund managers, driven by the firm's expertise in management company services, private equity, real estate, private debt and venture capital.
Anne Catherine’s appointment adds further weight to Crestbridge’s highly experienced Luxembourg team, who provides global, comprehensive support to fund managers. This includes managing the administrative, accounting, reporting, residency and governance needs of a broad range of fund structures throughout their lifecycles.
Prior to joining Crestbridge, Anne Catherine was the Partner in charge of Corporate Secretarial Services in Deloitte in Luxembourg. She has over 20 years' experience in Private Equity and Real Estate sectors.
Anne Catherine gained her extensive experience as part of the Management/Executive Committees of Arendt Services in Luxembourg, as well as in her position as Executive Director of Bedell (which became Ocorian), a Luxembourg Trust & Fund business of a Jersey Group. In both positions, she served as board members of various regulated and non-regulated clients’ entities. Anne Catherine’s area of activities included the compliance, corporate, governance, tax, internal control and risk management functions. She started her career as tax advisor in Ernst & Young in Luxembourg and New York, before transitioning into a Senior Tax Lawyer position at a Luxembourg Law Firm, Arendt.
Anne Catherine holds masters’ degrees in economics and in International & European law, a post-graduate diplomas in Political Sciences as well as in International Business Law. She is also qualified as a Certified International Control Specialist and has a qualification in risk management. She was a Chartered Accountant in Luxembourg and a qualified attorney in France and Luxembourg. Anne Catherine was the Chair of the ILA Company Secretary and Governance Officer Committee for 4 years. She remains an active member of such committee and is a speaker for the ILA Company Secretary and Governance Officer Committee certification.
Michael Johnson, Group Head of Institutional Services, Crestbridge, said:
“I'm delighted to welcome Anne Catherine to the team and am delighted that Crestbridge continues to be a business where top, global talent comes to work and thrive. Anne Catherine will be leading some of the best talent available in the region, people who are focused on delivering exceptional service and innovative solutions to our global client base. Anne Catherine offers the team not only considerable technical expertise but vast knowledge, having worked with some of the biggest names in the industry. I look forward to her playing a vital role in leading and driving forward our Luxembourg and international business.”
-ENDS-
Notes to editors
- We are a leading global administration, management & corporate governance solutions business.
- We provide a broad range of outsourced fiduciary, administrative, accounting, and compliance services globally – our expertise spans services, asset classes, and jurisdictions. Since 1998, we have been putting our insight and experience to work for clients who include leading corporations, sovereign wealth funds, investor groups, asset managers, and ultra-high net worth families.
- Crestbridge employs over 500+ people and has nine international offices: Bahrain, Cayman, Ireland, Jersey, London, Luxembourg, New Jersey, New York, and Southampton.
- We are regulated in our locations (see here for more details)
View source version on businesswire.com: https://www.businesswire.com/news/home/20220725005497/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
